Labiotech.eu

News and Trends 6 Feb 2015

2014, the Biggest Year Ever for European Biotech IPOs

There is no need to say it: biotechnology is the latest trend. A worldwide bio-boom has shaken stock markets throughout 2014. For European start-ups, last year represented a remarkable step forward as 15 companies went public and raised €719.8M in total, as Biocom’s last report states. Let me present you a review summering the major […]

February 6, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 4 Feb 2015

And now, Moderna signs a strategic partnership with prestigious Institut Pasteur

Moderna is the Biotech company that raised the biggest VC round ever ($450M) and which signs deals almost every week. It signed a $50M deal with Merck two weeks ago, and now signs a strategic partnership with prestigious Institut Pasteur from Paris through its new Venture Valera. Moderna is developing a proprietary mRNA therapeutics platform. Instead […]

February 4, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Feb 2015

AYOXXA raises its sights with a new agreement to develop ophthalmic diagnostic tools

New agreement was signed between AYOXXA, an international biotech company with headquarters in Cologne, and the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic […]

February 3, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 2 Feb 2015

Will 4D Pharma be UK’s next Microbiome leader?

4D Pharma, a biopharmaceutical company focusing on significant new therapeutic areas, plan to raise €46M to continue the development of its drugs candidates and to exploit its microbiome platform MicroRx. Will 4DPharma be the next UK’s microbiome leader? This English company, founded in early 2014, has focused its current interests solely in the microbiome field and the discovery […]

February 2, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 1 Feb 2015

Phenex sells out its main programme to Gilead

Gilead Sciences announces the acquisition of Phenex Pharmaceuticals’ development program for non-alcoholic steatohepatitis (NASH) and other liver diseases. Gilead Sciences and Phenex Pharmaceuticals announced the signing of a definitive agreement under which Gilead will acquire Phenex’s Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including non-alcoholic steatohepatitis […]

February 1, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 31 Jan 2015

An Anglo-French Partnership To Cure Hepatitis B

European biotechnology company Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial license agreement. This deal grants ITS the rights to research, develop and commercialize Hepatitis B vaccine candidates in combination with Valneva’s IC31 Adjuvant. Valneva’s IC31 Adjuvant is a unique synthetic adjuvant combining the immuno-stimulating properties […]

January 31, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Jan 2015

The Human Protein Atlas: exploring human geography

Some 20 years ago, before the genomic era, isolating a protein and identifying the tissue where it was present was enough to get a PhD. Swedish researchers just did it for all the proteins in the human body: the equivalent of 20,000 thesis from the pregenomic age, at a stroke. Thanks to the ‘omics’, the […]

January 30, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 27 Jan 2015

Italian Genenta Science’s Original Strategy to Treat Cancer

Tumor microenvironment, including tumor-associated macrophages, plays a key role in controlling tumor progression and response to therapies. It stimulates tumor growth, supports angiogenesis and tissue remodeling, as well as neutralizes host immunity. Genenta Science is using this mechanism, which is certainly a promising area of cancer biology for the identification of new therapeutic targets. In […]

January 27, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Jan 2015

Is Gecko’s Bio-inspired Glue going to revolutionize Heart Surgery and Tissue Repair?

Imagine you could use a glue to fix a hole or week zone inside your body. Sound promising? Definitely. A new generation of adhesive has been discovered. It can be used in a highly challenging environment and be activated by light. The illustration below shows you how it could be used in heart surgery. The […]

January 26, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 24 Jan 2015

Important Bilateral Academic Agreement for the Future of iPS Cell Therapy

The UK Cell Therapy programme Catapult, which is focused on the development of the UK cell therapy industry to increase the nation’s health and wealth, has signed a patent licence agreement with iPS Academia Japan. It represents a pivotal step in the development of the UK’s GMP induced pluripotent stem (iPS) cell bank. Under the […]

January 24, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 23 Jan 2015

A glimpse of the future: the revolution of bionic eyes

Six months after the surgery, the first Spanish with a bionic eye has gone from the total darkness to discern shapes and distances thanks to the technology developed by Second Sight Medical Products. With the MedTech field moving forward so fast, a new generation of devices meant to restore the sense of vision is about […]

January 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Jan 2015

Novabiotics Tackles Antibiotic Resistance by Raising €6,5M Euros

NovaBiotics Ltd has raised €6,5M for priority clinical stage first-in-class antimicrobial therapeutics assets. The private placement with Woodford Investment Management LLP was arranged by Shore Capital as financial adviser and broker to the company. NovaBiotics is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. NovaBiotics has spent more than 10 […]

January 22, 2015 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

2014, the Biggest Year Ever for European Biotech IPOs

And now, Moderna signs a strategic partnership with prestigious Institut Pasteur

AYOXXA raises its sights with a new agreement to develop ophthalmic diagnostic tools

Will 4D Pharma be UK’s next Microbiome leader?

Phenex sells out its main programme to Gilead

An Anglo-French Partnership To Cure Hepatitis B

The Human Protein Atlas: exploring human geography

Italian Genenta Science’s Original Strategy to Treat Cancer

Is Gecko’s Bio-inspired Glue going to revolutionize Heart Surgery and Tissue Repair?

Important Bilateral Academic Agreement for the Future of iPS Cell Therapy

A glimpse of the future: the revolution of bionic eyes

Novabiotics Tackles Antibiotic Resistance by Raising €6,5M Euros

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!